Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro forma cash of $716 million including recent ATM sales extends cash runway into second half of 2027Xen ...

Core Insights - Xenon Pharmaceuticals Inc. is advancing its Phase 3 portfolio, particularly focusing on azetukalner for epilepsy and neuropsychiatry, with significant milestones expected in the near future [1][2] Phase 3 Azetukalner Program in Epilepsy & Depression - The topline data for the X-TOLE2 Phase 3 study of azetukalner in focal onset seizures (FOS) is anticipated in March 2026, followed by a New Drug Application (NDA) submission in the second half of 2026 [4] - Five additional Phase 3 studies of azetukalner are ongoing, targeting various indications in epilepsy and neuropsychiatry, with topline data from the X-NOVA2 study in major depressive disorder (MDD) expected in the first half of 2027 [4][5] - The X-TOLE2 study has completed enrollment with 380 patients, and the data collected will support the upcoming topline readout [5] Broader Pipeline Opportunity - Azetukalner is a novel KV7 potassium channel opener, currently in late-stage clinical trials for epilepsy, MDD, and bipolar depression (BPD), representing a significant advancement in treatment options [7][10] - The company is also developing early-stage candidates targeting NaV1.7 and KV7 for pain management, with preliminary Phase 1 data expected in 2026 to support Phase 2 studies [11][12] About Epilepsy and Focal Onset Seizures - Epilepsy affects approximately 3 million adults in the U.S., with focal onset seizures being a common form that presents a substantial unmet medical need due to the inadequacy of existing treatments for many patients [9]

Core Insights - XOMA Royalty Corporation has amended its collaboration with Takeda, regaining a majority of the royalty interest in mezagitamab while diversifying its portfolio through a strategic royalty share transaction [1][2] Summary by Relevant Sections Collaboration with Takeda - The collaboration, originally established in 2006, has been amended to reduce Takeda's royalty and milestone payment obligations related to mezagitamab [1] - XOMA Royalty will now receive low to mid-single-digit royalties and milestone payments across nine development-stage assets in Takeda's externalized assets portfolio [1][2] Financial Implications - Prior to the amendment, XOMA Royalty held a mid-single-digit royalty and $16.25 million in potential milestones for mezagitamab [3] - Post-amendment, XOMA Royalty will retain a low single-digit royalty entitlement and up to $13.0 million in milestones for mezagitamab [3] Development-Stage Assets - The nine development-stage assets include: - **Osavampator**: Developed by Neurocrine Biosciences for major depressive disorder [4] - **Volixibat**: Developed by Mirum Pharmaceuticals for primary sclerosing cholangitis and primary biliary cholangitis [5] - **OHB-607**: A recombinant human IGF-1/IGFBP-3 for preventing bronchopulmonary dysplasia in premature infants, along with other early-stage assets from Oak Hill Bio [6] - **REC-4881**: An investigational MEK1/2 inhibitor for familial adenomatous polyposis, affecting approximately 50,000 people in the U.S. and Europe [7]

Core Insights - Neurocrine Biosciences announced that its investigational depression drug NBI-1070770 failed to meet its primary endpoint in a Phase II clinical trial, adding challenges to its collaboration with Takeda Pharmaceuticals [1][2] Group 1: Drug Information - NBI-1070770 is a selective oral NMDA receptor negative allosteric modulator developed for adults with major depressive disorder (MDD) who have insufficient response to at least one antidepressant [2] - The drug's development rights originated from a 2020 collaboration between Neurocrine and Takeda, where Takeda granted exclusive rights to seven investigational drugs, with NBI-1070770 being a key asset for depression [2] Group 2: Clinical Trial Details - The Phase II clinical trial started in March of the previous year, designed as a randomized, multi-center, double-blind, placebo-controlled study, enrolling 73 eligible MDD patients [2] - Patients were allocated in a 1:1:1:3 ratio to three different dosage groups of NBI-1070770 and a placebo group, with a treatment duration of four weeks [2] - The primary endpoint was assessed on day five of treatment using the Montgomery-Åsberg Depression Rating Scale (MADRS) to evaluate changes in depression severity from baseline [2] Group 3: Trial Results and Future Directions - Neurocrine stated that NBI-1070770 was generally well-tolerated during the trial, with no serious adverse events reported, but none of the dosage groups showed statistically significant differences compared to the placebo on the primary endpoint [2] - The Chief Medical Officer expressed disappointment over the results but noted that there are still aspects of the data worth further investigation, and the team will continue to analyze to determine future directions [2] - Despite the Phase II study not meeting its primary endpoint, Neurocrine has other ongoing projects in the depression field, including another drug, osavampator, which showed positive Phase II data and has entered Phase III clinical trials as of January 2025 [2]

after what we saw yesterday and now this morning following Cororeweave's earnings. Again, we just mentioned uh Megga Cap Tech uh MAX7 I should say, adding over $500 billion in market cap and this morning under pressure once again following Coree. Are you starting to get concerned about some of the volatility in the tech trade.>> I I think it's actually been pretty volatile for a while. Um I I made a call uh at the end of last year saying that a VIX which is like volatility of volatility uh would be elevated ...

Core Insights - Xenon Pharmaceuticals is entering a significant period with multiple clinical catalysts, including the completion of patient randomization in the Phase 3 X-TOLE2 study of azetukalner, with topline data expected in early 2026 [1][2] - The company has appointed Tucker Kelly as Chief Financial Officer to enhance its strategic finance capabilities ahead of the azetukalner launch [1][9] - Financial results for Q3 2025 show a net loss of $90.9 million, an increase from $62.8 million in Q3 2024, primarily due to higher research and development expenses [13][23] Clinical Development - The Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS) has completed patient enrollment with 380 patients randomized, and topline data is anticipated in early 2026 [7][14] - Ongoing Phase 3 studies include X-NOVA2 and X-NOVA3 for major depressive disorder (MDD) and X-CEED for bipolar depression (BPD), with recruitment continuing [6][16] - Azetukalner is a selective Kv7 potassium channel opener, currently in late-stage clinical development for epilepsy and neuropsychiatric disorders [3][17] Financial Overview - As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $555.3 million, down from $754.4 million at the end of 2024 [13] - Research and development expenses for Q3 2025 were $77.1 million, compared to $57.0 million in Q3 2024, reflecting increased costs associated with ongoing clinical studies [13][23] - General and administrative expenses rose to $19.3 million in Q3 2025 from $16.7 million in Q3 2024, primarily due to higher professional and consulting fees [13][23] Pipeline and Future Plans - The company is advancing its early-stage pipeline, including two first-in-human Phase 1 studies for lead molecules targeting Nav1.7 and Kv7 for pain management [5][12] - A Phase 1 study for NBI-921355, a sodium channel inhibitor in collaboration with Neurocrine Biosciences, is also underway [8] - Xenon plans to present new long-term safety and efficacy data at the upcoming American Epilepsy Society meeting in December 2025 [7]

Core Insights - Neurocrine Biosciences reported a strong Q3 performance, driven by significant sales growth from its products INGREZZA and CRENESSITY, achieving a 28% increase in product sales [1] Product Performance - INGREZZA and CRENESSITY were the primary contributors to the sales growth, indicating robust market demand and effective commercialization strategies [1] - The company’s product sales reached a notable milestone, reflecting the successful execution of its business model [1] Financial Highlights - The Q3 results exceeded market expectations, showcasing the company's strong financial health and operational efficiency [1] - The growth in product sales is a positive indicator for future revenue streams and overall company performance [1]

Company Overview - Xenon Pharmaceuticals reported a loss of $1.07 per share for Q2 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.03, compared to a loss of $0.75 per share in the same quarter last year [3] - The company did not generate any revenues in the reported quarter, similar to the year-ago quarter, due to the absence of a marketed product [4] Financial Performance - Research and development (R&D) expenses increased by 51% year over year to $75 million, driven by costs related to ongoing studies and a larger workforce [5] - General and administrative expenses were $19.2 million, remaining relatively flat year over year [5] - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $624.8 million, down from $691.1 million as of March 31, 2025 [6] Market Sentiment - There has been a downward trend in estimates revision for Xenon Pharmaceuticals over the past month [7] - The company has a poor Growth Score of F and a Momentum Score of D, resulting in an aggregate VGM Score of F [8] Industry Context - Xenon Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where Intellia Therapeutics, a peer, gained 9.4% over the past month [10] - Intellia Therapeutics reported revenues of $14.24 million for the last quarter, reflecting a year-over-year change of +104.6% [11]

Core Insights - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biopharmaceutical company focused on developing and acquiring technologies for medicine discovery and development [1] - The company operates in a competitive landscape with peers including Neurocrine Biosciences, Incyte Corporation, Alkermes plc, Myriad Genetics, and United Therapeutics Corporation [1] Financial Performance - Ligand's Return on Invested Capital (ROIC) is -3.48%, which is below its Weighted Average Cost of Capital (WACC) of 7.60%, indicating insufficient returns to cover capital costs [2] - Neurocrine Biosciences has a ROIC of 9.78% and a WACC of 5.47%, resulting in a ROIC to WACC ratio of 1.79, demonstrating effective capital utilization [3] - Incyte Corporation and United Therapeutics Corporation also exhibit strong ROIC to WACC ratios of 2.50 and 2.28, respectively, indicating efficient capital management [3] - Alkermes plc has the highest ROIC to WACC ratio of 2.93, suggesting it generates returns significantly above its cost of capital, making it an attractive investment [4] - Myriad Genetics shows a negative ROIC of -71.95% against a WACC of 10.96%, resulting in a ROIC to WACC ratio of -6.57, highlighting severe inefficiencies in capital utilization [4]

Core Insights - Nxera Pharma reported strong progress in the first half of 2025, with increasing revenues from its marketed products PIVLAZ® and QUVIVIQ®, and advancements in partnered programs [2][3][6] Operational Highlights - PIVLAZ® revenue increased by 7.6% from JPY 5,393 million to JPY 5,805 million compared to the prior corresponding period [6] - QUVIVIQ® generated JPY 1,586 million in revenue for the first half of 2025, with no sales in the prior corresponding period due to its launch in Q4 2024 [6] - Neurocrine Biosciences initiated Phase 3 trials for NBI-'568, resulting in a US$15 million payment to Nxera [6] - Nxera achieved a US$4.8 million milestone payment from Centessa Pharmaceuticals for the initiation of clinical development of ORX142 [6] Financial Highlights - Total revenue for the first half of 2025 was JPY 15,094 million (US$101.6 million), an increase of JPY 2,374 million (US$18.0 million) compared to the prior corresponding period [11] - R&D expenses rose to JPY 7,474 million (US$50.3 million), reflecting increased investment in R&D and currency impact [11] - SG&A expenses decreased to JPY 7,566 million (US$51.0 million), primarily due to targeted cost savings [11] - Operating loss improved to JPY 2,756 million (US$18.5 million) from JPY 3,654 million (US$24.0 million) in the prior corresponding period [11] - Net loss decreased to JPY 3,137 million (US$21.1 million) from JPY 4,703 million (US$30.9 million) in the prior corresponding period [11] - Cash and cash equivalents as of 30 June 2025 were JPY 32,997 million (US$228.1 million), an increase of JPY 729 million (US$22.3 million) from the beginning of the year [11] Pipeline and Future Outlook - Nxera is advancing a proprietary pipeline targeting obesity and chronic weight management, with over 30 active programs [5][10] - The company is well-positioned for significant value delivery for patients and shareholders with multiple key data readouts and new studies expected in the second half of 2025 [3][10]